Jeffrey S Weber
Affiliation: H. Lee Moffitt Cancer Center and Research Institute
- Immunotherapy for melanomaJeffrey Weber
Moffitt Cancer Center, Tampa, FL, USA
Curr Opin Oncol 23:163-9. 2011..This topic is timely, given the lengthy list of immune checkpoint inhibitors and vaccine formulations in development for melanoma...
- Current perspectives on immunotherapyJeffrey S Weber
H Lee Moffitt Cancer Center and Research Institute, Tampa, FL Electronic address
Semin Oncol 41:S14-29. 2014....
- At the bedside: adoptive cell therapy for melanoma-clinical developmentJeffrey S Weber
Moffitt Cancer Center and the Donald A Adam Comprehensive Melanoma Research Center, Tampa, Florida, USA
J Leukoc Biol 95:875-82. 2014..In the accompanying review, the preclinical work that supports the idea of adoptive cell therapy with TIL and expands the concept in promising new ways will be explored. ..
- Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanomaJeffrey Weber
Moffitt Cancer Center, Tampa, FL 33612, USA
Cancer Immun 13:7. 2013..This study demonstrated that ipilimumab can be combined safely with two chemotherapy regimens commonly used in advanced melanoma. ..
- Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanomaJeffrey S Weber
Donald A Adam Comprehensive Melanoma Research Center, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
Cancer 119:1675-82. 2013..Ipilimumab produced a characteristic spectrum of immune-related adverse events (irAEs) of special interest, consistent with its immune-based mechanism of action...
- Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trialJeffrey S Weber
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
Melanoma Res 21:530-4. 2011....
- Management of immune-related adverse events and kinetics of response with ipilimumabJeffrey S Weber
H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
J Clin Oncol 30:2691-7. 2012..We provide a detailed description of irAEs and recommendations for practicing oncologists who are managing them, along with the unusual kinetics of response associated with ipilimumab therapy...
- Cytotoxic T lymphocyte responses against melanocytes and melanomaGwendolen Y Chang
Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California, USA
J Transl Med 9:122. 2011..To uncouple vitiligo from melanoma destruction, it is important to understand if CTLs can respond against melanoma and melanocytes at different levels...
- Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse eventsJeffrey Weber
Comprehensive Melanoma Research Center, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
Oncologist 12:864-72. 2007....
- Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockadeJeffrey Weber
Moffitt Cancer Center, Donald A Adam Comprehensive Melanoma Research Center, Tampa, FL 33612, USA
Semin Oncol 37:430-9. 2010..Nonetheless, clinical investigators must be flexible and prepared to find that the biology of those systems may be very different in humans compared to mice...
- Tumor evasion may occur via expression of regulatory molecules: a case for CTLA-4 in melanomaJeffrey S Weber
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
J Invest Dermatol 128:2750-2. 2008....
- A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanomaJeffrey S Weber
Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida 33612, USA
Cancer 116:3683-91. 2010..The authors evaluated standard doses of dacarbazine combined with increasing doses of imexon to determine the maximal tolerated dose (MTD), toxicities, pharmacokinetics, and efficacy...
- Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanomaJeffrey Weber
USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA
J Immunother 31:215-23. 2008..The association of TTP with preexisting or induced Melan-A immunity supports future attempts to induce potent immunity to this antigen...
- A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanomaJeffrey Weber
Moffitt Cancer Center, Tampa, Florida 33612, USA
Clin Cancer Res 15:5591-8. 2009....
- Ipilimumab: controversies in its development, utility and autoimmune adverse eventsJeffrey Weber
H Lee Moffitt Cancer Center and Research Institute, Donald A Adam Comprehensive Melanoma Research Center, Department of Oncologic Sciences, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
Cancer Immunol Immunother 58:823-30. 2009....
- Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanomaJeffrey S Weber
Department of Oncologic Sciences, Moffitt Cancer Center, Tampa, FL, USA
Cancer 115:3944-54. 2009....
- White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapyJeffrey Weber
Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
Clin Cancer Res 17:1664-73. 2011..If successful, this approach will definitively answer the question of whether ACT can enter mainstream treatment for cancer...
- A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumorsJeffrey S Weber
Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL 33612
J Immunother 34:556-67. 2011..These results support further development of MKC1106-PP in specific clinical indications...
- Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010)Jeffrey Weber
H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, SRB 2, Tampa, Florida 33612, USA
Oncologist 13:16-25. 2008..Pending results from registration studies with ipilimumab and lessons learned from registration studies conducted with tremelimumab will help to define the role of anti-CTLA-4 blockade in the treatment of metastatic melanoma...
- Phase I/II study of ipilimumab for patients with metastatic melanomaJeffrey S Weber
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA
J Clin Oncol 26:5950-6. 2008..Secondary objectives included determination of a maximum-tolerated dose and assessment of clinical activity...
- Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanomaJeffrey S Weber
Moffitt Cancer Center, University of South Florida, Tampa, FL 33612, USA
J Immunother 35:89-97. 2012..These results suggest that ipilimumab can enhance immune responses mediated by different T-cell populations, and humoral immunity, in melanoma patients...
- Making dendritic cells from the inside out: lentiviral vector-mediated gene delivery of granulocyte-macrophage colony-stimulating factor and interleukin 4 into CD14+ monocytes generates dendritic cells in vitroRichard C Koya
Department of Medicine, UCLA Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
Hum Gene Ther 15:733-48. 2004..This article demonstrates the proof-of-concept to genetically convert monocytes to DC-type antigen-presenting cells with lentiviral vectors...
- Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinF Stephen Hodi
F Stephen Hodi, Anita Giobbie Hurder, Philip Friedlander, Jason J Luke, Katherine A Zukotynski, Jeffrey T Yap, Annick D Van den Abbeele, and George D Demetri, Dana Farber Cancer Institute Jonathan A Fletcher, Meijun Zhu, and Adrian Marino Enriquez, Brigham and Women s Hospital Donald Lawrence, Keith T Flaherty, and David E Fisher, Massachusetts General Hospital, Boston, MA Christopher L Corless, Michael C Heinrich, and Carol Beadling, Portland Veterans Administration Medical Center and Oregon Health and Science University, Portland, OR Philip Friedlander, Mount Sinai Medical Center, New York, NY Rene Gonzalez, University of Colorado Cancer Center, Aurora, CO Jeffrey S Weber, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL Thomas F Gajewski, University of Chicago, Chicago, IL Steven J O Day, Beverly Hills Cancer Center, Beverly Hills, Office of Analysis and Epidemiology
J Clin Oncol 31:3182-90. 2013..Amplifications and mutations in the KIT proto-oncogene in subsets of melanomas provide therapeutic opportunities...
- Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLsRaymond M Wong
Department of Medicine, University of Southern California, 1441 Eastlake Avenue, Room 6428, Los Angeles, CA 90033, USA
Int Immunol 19:1223-34. 2007..These findings have implications for developing new cancer immunotherapy strategies...
- Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanomaScott T Tagawa
Department of Medicine, Keck University of Southern California School of Medicine, Los Angeles, California, USA
Cancer 98:144-54. 2003....
- Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanomaJeffrey S Weber
Jeffrey S Weber, Ragini Reiney Kudchadkar, Bin Yu, Donna Gallenstein, Xiuhua Zhao, Alberto J Martinez, Wenshi Wang, Geoffrey Gibney, Jodi Kroeger, Cabell Eysmans, Amod A Sarnaik, and Y Ann Chen, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL and Christine E Horak and H David Inzunza, Bristol Myers Squibb, Princeton, NJ
J Clin Oncol 31:4311-8. 2013..Its safety, clinical efficacy, and correlative biomarkers were assessed with or without a peptide vaccine in ipilimumab-refractory and -naive melanoma...
- Biomarkers on melanoma patient T cells associated with ipilimumab treatmentWenshi Wang
Department of Cutaneous Oncology and the Donald A Adam Comprehensive Melanoma Research Center, H Lee Moffitt Cancer Center, Tampa, FL, USA
J Transl Med 10:146. 2012....
- Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanomaRaymond Wong
Department of Medicine, Keck University of Southern California School of Medicine, Los Angeles, California 90089, USA
Clin Cancer Res 10:5004-13. 2004..These data establish the immunogenicity of a class II epitope derived from a melanoma-associated antigen and support the inclusion of class II peptides in future melanoma vaccine therapies...
- The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodiesJeffrey S Weber
Department of Medicine, Keck School of Medicine, University of Southern California Norris Cancer Center, Los Angeles, California 90033, USA
Melanoma Res 16:379-83. 2006..Surprisingly, the reversal of the state of autoimmunity induced by cytotoxic T lymphocyte antigen 4 antibodies by the use of corticosteroids does not eliminate clinical benefit...
- Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trialJohn A Thompson
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
J Immunother 35:73-7. 2012..These retrospective analyses are the first to provide survival data for ipilimumab in treatment-naive and previously treated patients within the same clinical trial...
- Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanomaKristin Sanderson
Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
J Clin Oncol 23:741-50. 2005..MDX-010 pharmacokinetics and immune responses were secondary end points...
- A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanomaVinod Pullarkat
Department of Medicine, Divisions of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
Clin Cancer Res 9:1301-12. 2003....
- Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanomaScott T Tagawa
Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
Cancer 106:1353-7. 2006..Surgical resection of metastatic disease has been advocated to improve survival. Immunotherapy after metastasectomy may further improve the outcome for high-risk resected disease...
- Peptide-based vaccines for cancer immunotherapyJoeli A Brinkman
University of Southern California, 1501 San Pablo Street, ZNI 245, MC 2821, Los Angeles, CA 90089 2821, USA
Expert Opin Biol Ther 4:181-98. 2004....
- Current developments of immunotherapy in the clinicScott Antonia
H Lee Moffitt Comprehensive Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida 33612, USA
Curr Opin Immunol 16:130-6. 2004....
- 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?Jane L Messina
Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA the Departments of Pathology and Cell Biology, University of South Florida, Tampa, FL, USA
Sci Rep 2:765. 2012....
- Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene deliveryRichard C Koya
Institute for Genetic Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
J Immunother 26:451-60. 2003....
- Safety and tumor responses with lambrolizumab (anti-PD-1) in melanomaOmid Hamid
Angeles Clinic and Research Institute, Los Angeles, CA, USA
N Engl J Med 369:134-44. 2013..We tested the anti-PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma...
- The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanismsKim H T Paraiso
The Department of Molecular Oncology, The Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
Clin Cancer Res 18:2502-14. 2012..The clinical use of BRAF inhibitors is being hampered by the acquisition of drug resistance. This study shows the potential therapeutic use of the HSP90 inhibitor (XL888) in six different models of vemurafenib resistance...
- Peptide vaccine trials for melanoma: preclinical background and clinical resultsTony Talebi
Department of Medicine, Keck USC School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
Semin Cancer Biol 13:431-8. 2003
- CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issuesGiao Q Phan
Division of Cutaneous Oncology, H Lee Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
Ann Surg Oncol 15:3014-21. 2008..CTLA-4 blockade by means of monoclonal antibodies (ipilimumab and tremelimumab) has been evaluated in multiple clinical trials in patients with metastatic cancer, mainly those with melanoma and renal cell cancer...
- Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trialAntoni Ribas
Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA 90095, USA
Clin Cancer Res 17:2987-96. 2011..The goal of this study was to test the safety and activity of a therapeutic vaccine, MKC1106-MT, in patients with metastatic melanoma...
- Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanomaAmod A Sarnaik
Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida 33612, USA
Clin Cancer Res 17:896-906. 2011..To determine safety and feasibility of adjuvant ipilimumab following resection of high-risk melanoma and to identify surrogate markers for benefit...
- Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanomaJeffrey Weber
Department of Medicine, Division of Medical Oncology, Keck University of Southern California School of Medicine, Los Angeles, CA, USA
Cancer 97:186-200. 2003..Time to recurrence and survival were secondary end points...
- Therapeutic vaccination for HPV induced cervical cancersJoeli A Brinkman
Norris Comprehensive Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, CA 90089, USA
Dis Markers 23:337-52. 2007..Positive consequences of therapeutic vaccination would include less disfiguring treatment options and fewer instances of recurrent or progressive lesions leading to a reduction in cervical cancer incidence...
- Recent advances using anti-CTLA-4 for the treatment of melanomaAmod A Sarnaik
Department of Cutaneous Oncology, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
Cancer J 15:169-73. 2009..In this article, we review the spectrum of clinical trials involving CTLA-4 blockade and also review recent correlative studies attempting to elucidate the potential mechanisms by which CTLA-4 blockade achieves its therapeutic effects...
- PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cellsWenshi Wang
Donald A Adam Comprehensive Melanoma Research Center, Department of Immunology and Immunotherapy, Moffitt Cancer Center, 12902 Magnolia Drive, SRB 24324, Tampa, FL 33612, USA
Int Immunol 21:1065-77. 2009..PD-1 blockade also resulted in down-regulation of intracellular FoxP3 expression by Treg. These data suggest that PD-1 is importantly implicated in the regulation of Treg function in melanoma patients...
- Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory studyDongxin Liu
Department of Medicine, University of Southern California, Keck School of Medicine Norris Cancer Center, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
Clin Cancer Res 11:1237-46. 2005..The present exploratory study tested the hypothesis that cytokine gene polymorphisms predict clinical outcome in stage IV melanoma patients treated with biochemotherapy...
- Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma Peptide vaccineBrian Chiong
Department of Medicine and Molecular Microbiology Immunology, Keck University of Southern California School of Medicine, Los Angeles, California 90089, USA
J Immunother 27:368-79. 2004....
- Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgeryCheng Yu
Department of Radiation Oncology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
Int J Radiat Oncol Biol Phys 52:1277-87. 2002..To identify important prognostic factors predictive of survival and tumor control in patients with metastatic melanoma to the brain who underwent gamma knife radiosurgery...
- c-KIT signaling as the driving oncogenic event in sub-groups of melanomasKeiran S M Smalley
The Comprehensive Melanoma Research Center and the Department of Cutaneous Oncology, The Moffitt Cancer Center, Tampa, FL, USA
Histol Histopathol 24:643-50. 2009..The current review discusses the role of c-KIT signaling in melanoma progression and how this new information can be applied to the targeted therapy of melanoma...
- Peptide vaccines for cancerJeffrey Weber
USC Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Suite 3447, Los Angeles, CA 90089, USA
Cancer Invest 20:208-21. 2002..The cloning and identification of tumor antigens recognized by T-cells and data from initial clinical trials with peptides vaccines derived from those antigens are presented...
- Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorDouglas B Johnson
Douglas B Johnson and Jeffrey A Sosman, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center Jeffrey R Infante and Howard A Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN Keith T Flaherty and Donald P Lawrence, Massachusetts General Hospital Cancer Center, Boston MA Jeffrey S Weber and Geoffrey T Gibney, Moffitt Cancer Center, Tampa, FL Kevin B Kim and Gerald S Falchook, University of Texas MD Anderson Cancer Center, Houston, TX Richard F Kefford and Georgina V Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales Jonathan Cebon, Joint Ludwig Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia Omid Hamid, Angeles Clinic and Research Institute, Los Angeles Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA Lynn Schuchter, University of Pennsylvania Abramson Cancer Center Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA William H Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD Robert R McWilliams, Mayo Clinic
J Clin Oncol 32:3697-704. 2014..This study assessed the safety and efficacy of dabrafenib and trametinib in patients who had received prior BRAF inhibitor treatment...
- Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanomaYan Feng
Bristol Myers Squibb, Princeton, New Jersey, USA
Clin Cancer Res 19:3977-86. 2013..This retrospective analysis was conducted to characterize ipilimumab exposure-response relationships for measures of efficacy and safety in patients with advanced melanoma...
- Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarrayDaniel S Chen
Department of Internal Medicine Division of Oncology, Stanford University, Stanford, California, United States of America
PLoS Med 2:e265. 2005..In contrast to many animal model studies, immunotherapeutic trials in humans suffering from cancer invariably result in a broad range of outcomes, from long-lasting remissions to no discernable effect...
- Diversity and recognition efficiency of T cell responses to cancerTor B Stuge
Division of Hematology, Department of Medicine, Stanford University, Stanford, California, USA
PLoS Med 1:e28. 2004..Understanding why vaccine-elicited responses are beneficial in some patients but not in others will be important to improve targeted cancer immunotherapies...
- Tumor regression and autoimmunity in cytotoxic T lymphocyte-associated antigen 4 blockade-treated patientsJeffrey S Weber
Ann Surg Oncol 12:957-9. 2005
- Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cellsVinod Pullarkat
Division of Hematology, University of Southern California, Norris Cancer Center, 1441 Eastlake Avenue, MS 34, Los Angeles 90033, USA
J Immunol Methods 267:173-83. 2002..Due to the closed nature of the enrichment and culture systems, the potential for contamination is minimized. This protocol is well suited for culturing large numbers of DC for clinical immunotherapy trials...
- Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinomaJohn A Thompson
Seattle Cancer Care Alliance, 825 Eastlake Ave East, Mailstop G4 830, Seattle, WA 98109 1023, USA
J Clin Oncol 26:2034-9. 2008....
- Ex vivo identification, isolation and analysis of tumor-cytolytic T cellsValerie Rubio
Department of Medicine, Stanford University, 269 Campus Drive, Stanford, California 94305, USA
Nat Med 9:1377-82. 2003..The ability to rapidly identify and isolate tumor-cytolytic T cells would be very useful in cancer immunotherapy...
- A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanomaKarl D Lewis
University of Colorado, Cancer Center, 1665 North Ursula St, Mail Stop F 703, Aurora, CO 80045, USA
Invest New Drugs 24:89-94. 2006..In conclusion, Apomine, at the current dose studied, failed to produce a 30% progression free survival rate at 16 weeks considered to be a meaningful benefit for further development...
- IN VITRO/IN VIVO ACTIVATED DENDRITIC CELLS FOR MELANOMAJeffrey Weber; Fiscal Year: 2003....
- HPV DNA VACCINE FOR CERVICAL PRE NEOPLASIAJeffrey Weber; Fiscal Year: 2003..To insure that spontaneous regression does not account for a portion of the responses, baseline measurements will be followed one month later by a second set of assessments prior to the start of the vaccine. ..
- IL-12 as an Adjuvant for a Melanoma Peptide VaccineJeffrey Weber; Fiscal Year: 2003..The results of those assays will be used to design randomized phase III trials for resected high risk melanoma and to develop strategies for overcoming antigen-specific unresponsiveness in melanoma patients. ..
- Dendritic Cell Vaccination During Lymphoid ReconstitutionJeffrey Weber; Fiscal Year: 2008..Toxicity as well as clinical response will be secondary endpoints. The cohort with the optimal level of immune response will be taken forward in future studies. ..
- CTLA-4 Inhibition and Autoimmunity in MelanomaJeffrey Weber; Fiscal Year: 2008..abstract_text> ..